VIDAS ToRC panel

VIDAS ToRC panel

Serenity throughout pregnancy

The VIDAS ToRC panel includes 9 automated testsfor the screening and diagnosis of toxoplasmosis, rubella and cytomegalovirus (CMV) infections.

  • Complete solution
  • Proven high performance of IgG avidity tests
  • Cost-effective solution for small routine and confirmation testing
Brands:Biomerieux
Categories: ,
  • Description
  • Technical details

Description

The VIDAS® ToRC panel is a complete solution for the diagnosis and follow-up of the most important materno-fetal infections in pregnant women and newborns. Toxoplasmosis, Rubella and Cytomegalovirus (ToRC) infections are generally benign diseases. However when women are infected during pregnancy, consequences for the fetus can be dramatic. Our value-added IgG avidity tests help distinguish between recent and past infection, thus reducing the number of amniocenteses, and avoiding unnecessary treatment and stress for the future mothers.

A complete solution

  • 3 markers for accurate diagnosis

IgG: IgGs are widely used to determine the presence of specific immunity.

IgM: If IgMs appear earlier than IgGs, they also disappear earlier. This makes IgMs an early and sensitive marker of acute infection.

IgG avidity:

IgGs are initially of low avidity, but will mature to high avidity a few months after primary infection. A high IgG avidity index thus allows to rule out recently-acquired infection.

  • The VIDAS® ToRC solution
Toxoplasmosis Rubella Cytomegalovirus
VIDAS TOXO IgG II VIDAS RUB IgG VIDAS CMV IgG
VIDAS TOXO IgM VIDAS RUB IgM VIDAS CMV IgM
VIDAS TOXO Competition* VIDAS CMV IgG Avidity II
VIDAS TOXO IgG Avidity

Highly performant IgG avidity tests

VIDAS CMV IgG Avidity II

VIDAS CMV IgG Avidity II is a simple technique which enables weak avidity antibodies to be differentiated from high avidity antibodies. The detection of high avidity antibodies is a strong indication of a primary infection of more than 3 months, whereas the detection of weak avidity antibodies is a strong indication of a primary infection of less than 3 months.

A study conducted to assess VIDAS CMV IgG avidity II maturation kinetics on 135 sequential samples from 31 patients1 confirmed a very good correlation to clinical diagnosis:

  • No misclassification of recent infections (< 3 months)
  • No misclassification of past infections (> 3 months)
  • Best correlation over time from onset of infection compared to other commonly-used assays
  • Most regular avidity maturation pattern

VIDAS TOXO IgG Avidity

VIDAS TOXO IgG Avidity is a simple technique which enables weak avidity antibodies to be differentiated from high avidity antibodies. The detection of high avidity antibodies is a strong indication of a primary infection dating back more than 4 months.

  • Only FDA cleared Toxo IgG avidity test
  • Best performance for the exclusion of primary infection in patients with IgM and IgG positive results compared to other avidity assays2,3
  • The VIDAS system holds a reference position in the field of toxoplasmosis serology

Ease of use and cost-effectiveness

  • Single-dose, ready-to-use tests
  • Performed on the automated VIDAS immunoanalyzers, recognized worldwide for their flexibility, ease-of-use, reliability and 24/7 availability
  • Small packaging volumes
  • Ideal solution for small routine, confirmation of positive IgM, and IgG avidity testing
VIDAS ToRC panel
Parameter Reference Tests/kit Sample type Sample volume Time to result Calibration frequency
CMV IgG 30 204 60 Serum 100 µL 40 minutes 14 days
CMV IgM 30 205 30 Serum 100 µL 60 minutes 14 days
CMV IgG Avidity II 41 3557 30 Serum 2 x 100 µL 40 minutes No calibration
RUB IgG II 30 221 60 Serum, plasma 100 µL 40 minutes 14 days
RUB IgM 30 214 30 Serum 100 µL 60 minutes 14 days
TOXO IgG II 30 210 60 Serum, plasma 100 µL 40 minutes 14 days
TOXO IgG Avidity 30 222 30 Serum, plasma 2 x 100 µL 40 minutes No calibration
TOXO IgM 30 202 60 Serum 100 µL 40 minutes 14 days
TOXO Competition 30 211 60 Serum, plasma 125 µL 40 minutes 14 days